<DOC>
	<DOCNO>NCT02133742</DOCNO>
	<brief_summary>Despite substantial improvement patient outcome advanced RCC , durable complete response uncommon . The majority patient eventually develop resistance exhibit disease progression . Combining PD-1 inhibitor , show single-agent efficacy axitinib may provide additional clinical benefit compare axitinib alone .</brief_summary>
	<brief_title>A Dose Finding Study To Evaluate Safety , Drug Interaction , Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically cytologically confirm advanced RCC predominantly clearcell subtype primary tumor resect At least one measureable lesion define Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 . Eastern Cooperative Oncology Group performance status 0 1 Controlled hypertension Prior treatment systemic therapy advance RCC Prior adjuvant neoadjuvant therapy disease progression relapse occur within 12 month last dose treatment Prior treatment agent specifically target Tcell costimulation checkpoint pathway Active seizure disorder evidence brain metastasis , spinal cord compression , carcinomatous meningitis Diagnosis nonRCC malignancy occur within 2 year prior date randomization except adequately treat basal cell squamous cell skin cancer , carcinoma situ breast cervix low grade prostate cancer plan treatment intervention In past 12 month : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack In past 6 month : deep vein thrombosis pulmonary embolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Axitinib MK-3475</keyword>
	<keyword>patient advance Renal Cell Cancer .</keyword>
</DOC>